" class="no-js "lang="en-US"> OSE Immunotherapeutics Archives - Medtech Alert
Thursday, March 28, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

The OSE Immunotherapeutics Board of Directors Proposes the Appointment of Eric Leire, MD, as New Independent Director

OSE Immunotherapeutics, a biotech company dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation, today […]

OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer

OSE Immunotherapeutics SA has announced that the Spanish Drug Agency (Agencia Espanola de Medicamentos y […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more